The speed of new healthcare reform informatization, a new round of industry reshuffle or start

The year 2011 is the year when the new medical reforms achieve their phased goals.

As of now, there are only less than 3 months left before the deadline for the completion of the new medical reform. It is the most fundamental purpose of the new medical reform to solve the problem that it is difficult for people to see a doctor to see a doctor and reduce the burden of medical expenses on residents. The new medical reform in the long-awaited process has improved people's medical problems on the one hand, and has also aggravated the competitive pressures of the pharmaceutical industry on the other. A new round of industry reshuffle may begin.

How to effectively reduce the medical burden of the people is the core topic of the new medical reform. Therefore, discussions on price and cost are once again pushed to the cusp. The lack of previous competitiveness and the low cost of SMEs face the biggest challenge. For foreign drug companies, because the basic drug list of new medical reforms is valid, the old drug is relatively cheap, so it is very difficult for expensive foreign drugs to enter the basics. Drug directory. The reporter learned from related departments that in the near future it will also tie in with the relevant regulations on the proportion of essential medicines in non-primary-level medical institutions. This will inevitably have some impact on foreign companies that have occupied the high-end pharmaceutical market of the first terminal. Large prescription drugs and high-priced drugs will be restrained to a certain extent. Compared with these, leading enterprises with prominent core competitiveness will firmly grasp market expansion opportunities and benefit in the long term.

Yuan Antang’s staff told reporters that unlike other industries, the development of pharmaceutical companies bears more social responsibilities. To be a conscience company and provide benefits for the people is not only a moral norm in the future, but also a life and death choice that every company must face. Therefore, it is imperative to increase the level of science and technology, increase the core competitiveness, and reduce the prices of drugs.

Guangxi Yuanantang Pharmaceutical Co., Ltd., located in Darong Mountain, a “natural drug store” in Guangxi’s Liuwan Mountain, is a fixed asset of RMB 100 million. It integrates scientific research, technology, production and marketing, and has an annual production capacity of over 10%. Billion-scale national famous large-scale Chinese medicine pharmaceutical companies, the company was named "contractual and trustworthy" enterprise for nine consecutive years. Since its inception in 1992, it has grown rapidly, leading the domestic pharmaceutical industry in less than 20 years, relying on the cordial attention of the party and all levels of government, and the zealous support of all sectors of society and through the hard work of all employees.

Doing medicine well, selling medicine, and benefiting the people of the country, Yuan An Tang Pharmaceutical has never stopped its efforts for 20 years.

Behind the rapid development of Yuan An Tang is the strong support of the company’s industrial production level and capabilities.

With a modern production base and a high-tech industrial park, the registered drugs include 29 pharmaceutical dosage forms, more than 400 varieties, and have their own independent intellectual property rights, the main products of the skin yinjie compound yellow pine lotion, skin yinjie compound yellow pine wipes , Yinhu Ganmao San, Weiwei San, Zhuhu Huayu, Yinhu Anti-Infective Mixture are Chinese medicine products that have been approved by the State Food and Drug Administration as the “Guozi Quasi Character” approval number, and AX-Antibacterial lotion has filled The gap of domestic Chinese medicine against AI has been affirmed by people from all walks of life and has repeatedly won the national certification.

Another important force supporting the continued rapid development of Yuan An Tang comes from the company’s research capabilities.

At present, Yuan An Tang has a core team of doctors and masters in technology research and development. It has established strategic cooperation relationships with a number of scientific research institutes such as the Chinese Academy of Sciences and Chinese Academy of Sciences, and has undertaken the national “863 Program” and a national major new drug creation technology project. There are more than 30 major science and technology projects and major provincial science and technology projects such as state industrial upgrading and technological transformation projects, national multiplication projects, electronic fund industrial projects, and so on. This year, relying on advanced scientific research strength, Yuan An Tang began to focus on creating the “Gui Medicine” brand. As a kind of tribute in the feudal society, cinnamon is of great value both in medicine and in food. The chief pharmacist, Mo Zhaoqin, believes that: Cinnamon combines food and medicine for one, with a warm stomach to stop diarrhea, sterilization, pass through, cold and dampness, antitussive and antitussive, diuretic, anti-radiation, increase white blood cells, blood pressure, control blood sugar balance, etc. Many effects. However, due to the influence of many factors, related development research has always been regarded as "a difficult piece of bone." However, Mo Zhaoqin's exact path is difficult to change. He took his team of Yuan An Tang to do in-depth research on the authentic Chinese herbal medicine Xijiang Cinnamon. Once successful, it will inevitably be a feat in the industry.

The rapid development of the source Antang is inseparable from the rational deployment of strategic operations and stepwise deployment of resources. For six years in a row, performance has doubled and led the leading companies in the pharmaceutical industry. This is an expectation and a spur, and the heart of the strong Chinese pharmaceutical companies is worth the wait.